NeuroSense Therapeutics has successfully completed a phase IIa clinical trial with their current combination drug PrimeC, illustrating the safety and tolerability of the pharmaceutical. Furthermore, initial signs of efficacy were observed as the overall disease decline was slower when compared to matched PRO-ACT placebo arm.

NeuroSense has also received a patent allowance in the US for PrimeC and expects to submit further patents based on clinical data.